A Multifaced Aspect of Clostridium difficile Infection in Pediatric Patients with Inflammatory Bowel Disease: Case Series and Literature Review.
Elena IanaCatalin BobocAndreea Gabriela VladMaria Teodora IlieMalina AnghelAnca Andreea BobocAndreea IoanMara-Ioana IeșanuLiana GavriliuFelicia GalosPublished in: Journal of personalized medicine (2023)
Children with inflammatory bowel disease (IBD) have an increased susceptibility to Clostridium difficile infection (CDI), with a rising incidence over time. Differentiating between CDI and IBD exacerbation is challenging due to overlapping symptoms. In our cohort of 55 pediatric IBD patients, 6 were diagnosed with CDI. Upon conducting a thorough patient evaluation and subsequent data analysis, an exhaustive review of the existing literature was undertaken. CDI is more prevalent in ulcerative colitis (UC) than Crohn's disease (CD) patients, as seen in our patients and in the existing literature. The management of a pediatric patient with IBD is itself a challenge for a clinician because of the chronic, possibly relapsing course, and substantial long-term morbidity. When CDI is added, it becomes even more demanding, since CDI leads to more severe disease in children with IBD. A multidisciplinary approach and intensive treatment for possible sepsis, anemia, hypoalbuminemia, and hydro-electrolytic and acid-base imbalances are frequently mandatory in patients with CDI and IBD, which leads to a significant health care burden in hospitalized children with IBD. After the infection is treated with antibiotic therapy, important considerations regarding the future treatment for the underlying IBD are also necessary; in most cases, a treatment escalation is required, as also seen in our study group.
Keyphrases
- ulcerative colitis
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- healthcare
- peritoneal dialysis
- data analysis
- young adults
- multiple sclerosis
- systematic review
- prognostic factors
- chronic obstructive pulmonary disease
- computed tomography
- risk factors
- magnetic resonance imaging
- mesenchymal stem cells
- clinical trial
- patients with inflammatory bowel disease
- rheumatoid arthritis
- patient reported outcomes
- magnetic resonance
- depressive symptoms
- early onset
- combination therapy
- patient reported
- systemic lupus erythematosus
- disease activity
- health insurance